Welcome to our dedicated page for Natera news (Ticker: $NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Natera's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Natera's position in the market.
Natera, Inc. announced a new publication in JCO Precision Oncology showcasing the effectiveness of its Signatera test in detecting breast cancer recurrence early. The study involved 156 early-stage breast cancer patients followed for up to 12 years post-surgery. Signatera detected relapse 38 months earlier than imaging, with an 88.2% sensitivity rate. Patients testing positive for ctDNA had worse survival outcomes. The study emphasizes the importance of early recurrence detection and long-term monitoring in breast cancer patients.
Natera, Inc. (NASDAQ: NTRA) will report its first quarter 2024 results on May 9. The company is a global leader in cell-free DNA and genetic testing. The earnings conference call will take place at 1:30 p.m. PT (4:30 p.m. ET) on the same day.
Natera, Inc. (NASDAQ: NTRA) has launched a new cfDNA-based fetal RhD test to support Ob/Gyn physicians and patients during a nationwide shortage of RhIg therapy. The test offers 100% sensitivity and >99% specificity, and can be conducted as early as nine weeks gestation. This initiative is important to prevent complications from alloimmunization in pregnancies where the maternal blood type is RhD-negative and the fetal blood type is RhD-positive. The product launch was supported by a large clinical validation study with over 650 patients, demonstrating Natera's commitment to accurate and reliable diagnostics in women's health.
